Unlocking the Economic Potential of Dementia Research: A Call for Increased Investment

By HEOR Staff Writer

July 17, 2023

UK government funding for dementia research has declined from its peak in 2018-2019. Despite this, the field shows high potential for research in the coming years. By 2040, over 1.2 million people in the UK are expected to have dementia, a 30% increase from 2022. The economic benefits of dementia research can be measured through an economic impact assessment (EIA), which considers various dimensions of dementia research. The report also highlights the significant impact of COVID-19 on people with dementia.

  • Dementia research in 2019/20 generated 7,353 full-time equivalent (FTE) jobs and contributed over £529 million in gross value added (GVA) to the UK economy.
  • Directly, dementia research supported 2,607 FTE jobs, including 2,059 research/scientific and technical roles and 548 administrative roles, contributing over £276 million in GVA.
  • Indirectly, dementia research supported and created 4,746 FTE jobs, contributing over £252 million in GVA.
  • Full-time salaries in dementia R&D and administration are, on average, 41% and 24.5% higher respectively than the average salary across all jobs in a region.

The risk of developing dementia or becoming an informal carer for a person with dementia is high. The study found that every £1 invested in dementia research generated £2.59 of economic benefit in the UK during 2019/20, and this is expected to increase to £2.91 on average in the next 20 years. Thus, increased investment in dementia research could improve the lives of those affected by dementia and create long-term economic growth in the UK.

Reference url

Recent Posts

FDA Approval Lumvoa Therapeutics
FDA Approval Lumvoa Therapeutics Redefines Treatment Landscape for Thyroid Eye Disease

By João L. Carapinha

June 29, 2026

The FDA Approval Lumvoa Therapeutics delivers the first full insulin-like growth factor-1 receptor (IGF-1R) antagonist for thyroid eye disease (TED), a rare autoimmune condition that triggers orbital inflammation, proptosis, diplopia, pain, and risk of vision loss.
HIV Treatment Access
Public-Private Partnership Enhances HIV Treatment Access Through Innovative Drug Integration

By João L. Carapinha

June 29, 2026

A new agreement between Merck and the ADAP Crisis Task Force significantly advances HIV Treatment Access by integrating the newly approved single-tablet regimen IDVYNSO™ (doravirine/islatravir) into state AIDS Drug Assistance Programs that served more than 250,000 people with HIV in 2024.
EMA CHMP Meeting Highlights
Regulatory Insights from EMA CHMP Meeting Highlights

By HEOR Staff Writer

June 26, 2026

The EMA CHMP Meeting Highlights from 22-25 June 2026 show the committee advancing six new medicines while maintaining rigorous evidentiary standards for complex and rare conditions. Positive opinions covered an inactivated influenza vaccine for adults 50 and older, a levodopa-carbidopa intestinal...